Logo

Scilex Holding Company

SCLX

Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscou… read more

Healthcare

Drug Manufacturers—General

5 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$6.56

Price

-1.58%

-$0.11

Market Cap

$55.703m

Small

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financial Reports

Key metrics over the past few years and other important metrics. Amounts in USD.

-452.8%

EBITDA Margin

-502.4%

Net Profit Margin

-48.3%

Free Cash Flow Margin

-452.8%

EBITDA Margin

-502.4%

Net Profit Margin

-48.3%

Free Cash Flow Margin
Revenue

$33.862m

+11.9%

1y CAGR

-4.5%

3y CAGR

+2.3%

5y CAGR
Earnings

-$419.677m

-17.0%

1y CAGR

-124.5%

3y CAGR

-190.7%

5y CAGR
EPS

-$38.87

-6.6%

1y CAGR

-12.5%

3y CAGR

-168.5%

5y CAGR
Book Value

-$254.070m

$293.635m

Assets

$547.705m

Liabilities

$106.359m

Debt
Debt to Assets

36.2%

-0.3x

Debt to EBITDA
Free Cash Flow

-$6.590m

-278.9%

1y CAGR

-56.7%

3y CAGR

-40.1%

5y CAGR
No items found.
Press Releases
Statements and updates from the company
↑ TopSummaryPriceFinancialsPress Releases